RGNX
No price yet
Announcements
Nothing here yet
Daily updates
FDA designations
Nothing here yet
News
- REGENXBIO presents positive three-year durability data for surabgene lomparvovec in diabetic retinopathySep 25, 2026
- REGENXBIO presents positive long-term data for Surabgene Lomparvovec in wet AMD and diabetic retinopathyJul 19, 2026
- REGENXBIO dosed the first patient in the Phase IIb/III NAAVIGATE trial and became eligible for a $100 million milestone paymentJun 29, 2026
- REGENXBIO completed dosing in the confirmatory RGX-202 study, supporting a planned BLA submission in Q3 2026Jun 24, 2026
- REGENXBIO aligned with FDA on the path toward resubmitting the NAVSUNLI BLA for accelerated approval in MPS IIJun 22, 2026